Volume 6, Number 4—August 2000
Reply to Drs. Angulo and Collignon
To the Editor: Drs. Angulo and Collignon point out that exposure to one antimicrobial drug (e.g., tetracycline) can confer a selective advantage to a multiresistant organism (e.g., R-type ACSSuT) over nonresistant organisms. However, tetracycline use would not be expected to favor one tetracycline-resistant organism (MR-DT104) over other tetracycline-resistant organisms, and most bovine Typhimuriums before the MR-DT104 epidemic were tetracycline-resistant R-type ASSuT. Since neither florfenicol nor chloramphenicol was then available for use in livestock in the United States, the evidence suggests that the emergence of MR-DT104 in cattle populations was not driven by antibiotic selection pressure. The references Drs. Angulo and Collignon cited to establish the importance of antimicrobial use in livestock for the dissemination of multiresistant clones either do not address the issue of dissemination (1-2) or present evidence to the contrary: the dissemination of fluoroquinolone-resistant MR-DT104 despite the lack of fluoroquinolone use in the herds in question (3).
Available data support Dr. Collignon's example of Campylobacter as an agent for which fluoroquinolone use in livestock resulted in increasing prevalence of fluoroquinolone resistance (4). However, the epidemiology of resistance in polyclonal commensals such as Campylobacter is very unlike that of epidemic, clonal S. Typhimuriums. The epidemic, clonal dissemination of S. Typhimurium more closely resembles that of methicillin-resistant Staphylococcus aureus (MRSA). Epidemic MRSA clones differ genetically from nonepidemic ones, and dissemination of epidemic clones does not necessarily require antimicrobial selection pressure (5). Because antimicrobial usage practices that contribute to the control of MRSA have not been scientifically defined, infection control practices must play the central role in successful MRSA control programs (6-8).
Dr. Angulo's hypothesis that MR-DT104 emerged genetically in Asian fish is plausible, but other credible hypotheses exist. tet(G), first described in Vibrio angullarium, also occurs in Pseudomonas aeruginosa (9). Similarly, floR is closely related to the P. aeruginosa chloramphenicol-resistance gene cmlA (10), and pse-1 encoded beta-lactamase is a common feature of hospital P. aeruginosa isolates (11). Thus, the hypothesis that MR-DT104 acquired resistance genes horizontally from nosocomial pseudomonads might also be worthy of consideration.
Salmonella infections acquired in other countries are frequently diagnosed in travelers recently returned to the United States. Although transmission of these infections to other humans may be rare in the United States, human-to-bovine transmission may occur regularly: thousands of cases of bovine Taenia saginata cysticercosis occurred immediately before and during the dissemination of MR-DT104. As humans are the only definitive host of the T. saginata tapeworm, these cases confirm the large-scale occurrence of human-to-animal transmission of enteropathogenic agents in the United States. Since transmission of S. Typhimurium from herd to herd is common in the United States, increased emphasis on Salmonella infection control may be an effective method for reducing dissemination of organisms such as MR-DT104.
With or without imposition of stringent controls on antibiotic use in the United States and Europe, the future genetic emergence of new epidemic clones of S. Typhimurium somewhere in the world is highly likely, and controlling the dissemination of epidemic clones is essential to avoid increasing problems with multidrug resistance. Certainly we do not disagree with the concept of reducing antimicrobial use, particularly such frivolous use as in calf milk replacers. However, we urge public health officials to consider that infection control is as central to control of agents such as MR-DT104 as it is for epidemic MRSA.
- Cohen ML, Tauxe RV. Drug-resistant Salmonella in the United States: an epidemiologic perspective. Science. 1986;234:964–9.
- Glynn MK, Bopp C, Dewitt MS, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype Typhimurium DT104 infections in the United States. N Engl J Med. 1998;338:1333–8.
- Mølbak K, Baggesen DL, Aarestrup FM, Ebbesen JM, Engberg J, Frydendahl K, An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104. N Engl J Med. 1999;341:1420–5.
- Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med. 1999;340:1525–32.
- Papakyriacou H, Vaz D, Simor A, Louie M, McGavin MJ. Molecular analysis of the accessory gene regulator (agr) locus and balance of virulence factor expression in epidemic methicillin-resistant Staphylococcus aureus. J Infect Dis. 2000;181:990–1000.
- Wagenvoort JHT. Dutch measures to control MRSA and the expanding European Union. Eurosurveillance. 2000;5:26–8.
- Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals. Proc Natl Acad Sci U S A. 2000;97:1938–43.
- McGowan JE Jr. Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol. 2000;21(Suppl):S36–43.
- Ng LK, Mulvey MR, Martin I, Peters GA, Johnson W. Genetic characterization of antimicrobial resistance in Canadian isolates of Salmonella Serovar Typhimurium DT104. Antimicrob Agents Chemother. 1999;43:3018–21.
- Briggs CE, Fratamico PM. Molecular characterization of an antibiotic resistance gene cluster of Salmonella typhimurium DT104. Antimicrob Agents Chemother. 1999;43:846–9.
- Pitt TL, Livermore DM, Miller G, Vatopoulos A, Legakis NJ. Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. J Antimicrob Chemother. 1990;26:319–28.
Suggested citation: Davis MA, Hancock DD, Besser TE, Rice DH, Gay JM. Reply to Drs. Angulo and Collignon [letter]. Emerg Infect Dis [serial on the Internet]. 2000, Aug [date cited]. Available from http://wwwnc.cdc.gov/eid/article/6/4/00-0430
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: December 16, 2010
- Page last updated: December 16, 2010
- Page last reviewed: December 16, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)